Cross-platform Comparison of Quantitative Florbetapir Amyloid PET Using MIMneuro and Neurophet SCALE PET

Background: Quantitative amyloid PET is increasingly used in clinical practice, but the interchangeability of quantification software remains uncertain. We compared quantitative amyloid PET measurements, diagnostic performance, and platform-specific thresholds between two FDA-cleared software packages, MIMneuro and Neurophet SCALE PET, using clinical Florbetapir 18 F-PET/CT. Patients and Methods: In this retrospective single-center study, 95 consecutive patients who underwent Florbetapir 18 F-PET/CT were independently analyzed using MIMneuro and Neurophet SCALE PET. Quantitative measures included standardized uptake value ratios (SUVRs) and global Centiloid values. Cross-platform agreement was evaluated using Pearson correlation, Bland–Altman analysis, and Cohen κ statistics. Receiver operating characteristic analysis was used to determine platform-specific thresholds for predicting visual amyloid positivity. Results: Regional SUVRs showed moderate correlations ( r = 0.414 to 0.674; all P < 0.001), with the strongest correlation observed for global Centiloid values ( r = 0.684). Neurophet yielded significantly higher global SUVR values than MIMneuro (mean bias, −0.20; P < 0.001), whereas the difference in Centiloid values was not significant. The optimal thresholds for predicting visual amyloid positivity were 1.10 versus 1.40 for global SUVR and 20.7 versus 34.4 for global Centiloids for MIMneuro and Neurophet, respectively. Cross-platform agreement was moderate using SUVR (κ = 0.42) and improved with Centiloids (κ = 0.60). Conclusions: Although MIMneuro and Neurophet SCALE PET showed moderate agreement, their quantitative measurements were not directly interchangeable at clinically relevant thresholds. These findings suggest that platform-specific quantitative thresholds may be needed when amyloid PET is used for clinical interpretation, longitudinal follow-up, or selection of patients for antiamyloid therapy.

Authors

Institutions

Publication Details

Journal
Clinical Nuclear Medicine
Published
2026-11-09
DOI
https://doi.org/10.1097/rlu.0000000000006764
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cross-platform Comparison of Quantitative Florbetapir Amyloid PET Using MIMneuro and Neurophet SCALE PET

Mehmet Aksakal, Charles H. Watt, Noha Aboueldahab, Murat Sadıç et al.
Clinical Nuclear Medicine
Dementia and Cognitive Impairment Research
article

Cross-platform Comparison of Quantitative Florbetapir Amyloid PET Using MIMneuro and Neurophet SCALE PET

Mehmet Aksakal, Charles H. Watt, Noha Aboueldahab, Murat Sadıç, David H. Lewis, Mona Kharaji, Hisham Alfarra, Mahmud Mossa Bosha
article en

Abstract

Background: Quantitative amyloid PET is increasingly used in clinical practice, but the interchangeability of quantification software remains uncertain. We compared quantitative amyloid PET measurements, diagnostic performance, and platform-specific thresholds between two FDA-cleared software packages, MIMneuro and Neurophet SCALE PET, using clinical Florbetapir 18 F-PET/CT. Patients and Methods: In this retrospective single-center study, 95 consecutive patients who underwent Florbetapir 18 F-PET/CT were independently analyzed using MIMneuro and Neurophet SCALE PET. Quantitative measures included standardized uptake value ratios (SUVRs) and global Centiloid values. Cross-platform agreement was evaluated using Pearson correlation, Bland–Altman analysis, and Cohen κ statistics. Receiver operating characteristic analysis was used to determine platform-specific thresholds for predicting visual amyloid positivity. Results: Regional SUVRs showed moderate correlations ( r = 0.414 to 0.674; all P < 0.001), with the strongest correlation observed for global Centiloid values ( r = 0.684). Neurophet yielded significantly higher global SUVR values than MIMneuro (mean bias, −0.20; P < 0.001), whereas the difference in Centiloid values was not significant. The optimal thresholds for predicting visual amyloid positivity were 1.10 versus 1.40 for global SUVR and 20.7 versus 34.4 for global Centiloids for MIMneuro and Neurophet, respectively. Cross-platform agreement was moderate using SUVR (κ = 0.42) and improved with Centiloids (κ = 0.60). Conclusions: Although MIMneuro and Neurophet SCALE PET showed moderate agreement, their quantitative measurements were not directly interchangeable at clinically relevant thresholds. These findings suggest that platform-specific quantitative thresholds may be needed when amyloid PET is used for clinical interpretation, longitudinal follow-up, or selection of patients for antiamyloid therapy.

Clinical Nuclear Medicine
University of Washington (US), University of Alabama at Birmingham (US), University of Colorado Anschutz Medical Campus (US)
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon